Medsci 11 00015 v2
Medsci 11 00015 v2
Medsci 11 00015 v2
sciences
Systematic Review
Prevention and Treatment of Chemotherapy-Induced Peripheral
Neuropathy (CIPN) with Non-Pharmacological Interventions:
Clinical Recommendations from a Systematic Scoping Review
and an Expert Consensus Process
Nadja Klafke 1, *, Jasmin Bossert 1 , Birgit Kröger 2 , Petra Neuberger 3 , Ute Heyder 4 , Monika Layer 5 ,
Marcela Winkler 6 , Christel Idler 6 , Elke Kaschdailewitsch 7 , Rolf Heine 8 , Heike John 9 , Tatjana Zielke 9 ,
Beeke Schmeling 9 , Sosamma Joy 10 , Isabel Mertens 10 , Burcu Babadag-Savas 9 , Sara Kohler 11 ,
Cornelia Mahler 12 , Claudia M. Witt 13 , Diana Steinmann 9 , Petra Voiss 10 and Regina Stolz 2
1 Department of General Practice and Health Services Research, University Hospital Heidelberg,
69120 Heidelberg, Germany
2 Institute for General Practice and Interprofessional Care, University Hospital Tübingen,
72076 Tübingen, Germany
3 National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany
4 Women’s Clinic, Community Hospital Karlsruhe, 76133 Karlsruhe, Germany
5 Center for Integrative Medicine, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland
6 Department of Naturopathy and Integrative Medicine, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany
7 Center for Integrative Oncology, Die Filderklinik, 70794 Filderstadt-Bonlanden, Germany
8 Anthroposophic Nursing Network in Germany, Academy for Nursing Professions at the Filderklinik,
Die Filderklinik, 70794 Filderstadt-Bonlanden, Germany
9 Clinic for Radiation Therapy and Special Oncology, Hannover Medical School, 30625 Hannover, Germany
10 Department of Internal and Integrative Medicine, Evang. Kliniken Essen-Mitte, Faculty of Medicine,
Citation: Klafke, N.; Bossert, J.; University of Duisburg-Essen, 45136 Essen, Germany
11 Department of Health, Zurich University of Applied Sciences, 8401 Winterthur, Switzerland
Kröger, B.; Neuberger, P.; Heyder, U.;
12 Department of Nursing Science, Institute of Health Sciences, University Hospital Tübingen,
Layer, M.; Winkler, M.; Idler, C.;
72076 Tübingen, Germany
Kaschdailewitsch, E.; Heine, R.; et al. 13 Institute for Complementary and Integrative Medicine, University Hospital Zürich and University of Zürich,
Prevention and Treatment of
8091 Zürich, Switzerland
Chemotherapy-Induced Peripheral
* Correspondence: nadja.klafke@med.uni-heidelberg.de
Neuropathy (CIPN) with
Non-Pharmacological Interventions:
Abstract: Background: Most individuals affected by cancer who are treated with certain chemother-
Clinical Recommendations from a
apies suffer of CIPN. Therefore, there is a high patient and provider interest in complementary
Systematic Scoping Review and an
Expert Consensus Process. Med. Sci.
non-pharmacological therapies, but its evidence base has not yet been clearly pointed out in the
2023, 11, 15. https://doi.org/ context of CIPN. Methods: The results of a scoping review overviewing the published clinical
10.3390/medsci11010015 evidence on the application of complementary therapies for improving the complex CIPN symp-
tomatology are synthesized with the recommendations of an expert consensus process aiming to
Academic Editor: Tracy Murray-Stewart
draw attention to supportive strategies for CIPN. The scoping review, registered at PROSPERO
Received: 2 August 2022 2020 (CRD 42020165851), followed the PRISMA-ScR and JBI guidelines. Relevant studies pub-
Revised: 14 December 2022 lished in Pubmed/MEDLINE, PsycINFO, PEDro, Cochrane CENTRAL, and CINAHL between
Accepted: 23 December 2022 2000 and 2021 were included. CASP was used to evaluate the methodologic quality of the studies.
Published: 30 January 2023 Results: Seventy-five studies with mixed study quality met the inclusion criteria. Manipulative
therapies (including massage, reflexology, therapeutic touch), rhythmical embrocations, movement
and mind–body therapies, acupuncture/acupressure, and TENS/Scrambler therapy were the most
frequently analyzed in research and may be effective treatment options for CIPN. The expert panel
Copyright: © 2023 by the authors.
Licensee MDPI, Basel, Switzerland.
approved 17 supportive interventions, most of them were phytotherapeutic interventions including
This article is an open access article external applications and cryotherapy, hydrotherapy, and tactile stimulation. More than two-thirds of
distributed under the terms and the consented interventions were rated with moderate to high perceived clinical effectiveness in ther-
conditions of the Creative Commons apeutic use. Conclusions: The evidence of both the review and the expert panel supports a variety of
Attribution (CC BY) license (https:// complementary procedures regarding the supportive treatment of CIPN; however, the application on
creativecommons.org/licenses/by/ patients should be individually weighed in each case. Based on this meta-synthesis, interprofessional
4.0/).
healthcare teams may open up a dialogue with patients interested in non-pharmacological treatment
options to tailor complementary counselling and treatments to their needs.
1. Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) develops due to neurotoxic
treatments, in particular taxanes, vinca alkaloids, platinum agent, proteasome inhibitors,
and thalidomide [1]. Such treatments attack the cellular and sub cellular level and cause
altered ion channel activity (sodium, potassium, calcium) as well as changes in the in-
tracellular systems, which are responsible for oxidative stress, neuroinflammation, and
mitochondrial dysfunction [2,3]. In contrast to nociceptive pain, which occurs when a
painful stimulus activates the peripheral nociceptors, neuropathic pain is not the result of
damaged tissue, but is caused by inner structural deficits in the peripheral neurons and
sensory nerves [2,3]. Unpleasant CIPN symptoms appear in a variety of ways. Patients
often experience numbness in their feet and palms as well as paresthesia, acroataxia, and
the loss of motor functions, which contribute to the fact that patients with CIPN have a
high risk for falling injuries [4]. For many patients, even opening a water bottle is painful
or they feel like “walking on glass” [4] (a statement of some experts participating in the
symposium, see phase 2 under 2.2 “Structured expert consensus process”). Up to 71% of pa-
tients undergoing acute treatment (e.g., Oxaliplatin, Docetaxel) experience CIPN [5], and it
is one of the major symptoms that affects why patients may decide to cease their treatment.
Patients who develop CIPN are both at younger and older age, experience restrictions in
their quality-of-life functions, and therefore need effective treatment options [6]. Up to 42%
of patients experience CIPN two years after they started their taxane- and platinum-based
chemotherapy [7], and they are also in need for effective strategies for improving their
symptoms and increasing their quality of life [8].
Currently, there are not enough conventional CIPN treatments available, and the
most prescribed medication is Duloxetine, even though its effect size has been reported
to be moderate [9,10]. With the help of a systematic review, Hou et al. 2018 [1] identified
26 other treatment options in 35 included studies that were also on laser therapy and
acupuncture. The results, however, need to be considered with caution, as most studies
had small sample sizes and a variety of outcome measures. Hence, there is a need for
pointing out further treatment options to alleviate CIPN symptoms in order to relieve the
suffering of those affected. This is also shown in the fact that research indicates that up
to 80% of patients with cancer have an interest in so-called natural, non-pharmacological,
complementary interventions for self-managing their symptoms and actively take control
in their own symptom management [11,12]. Surveys have also identified an increase
of cancer patients’ use of complementary therapies from the timepoint before to after a
cancer diagnosis [13]. In this course of time, for example, the use of biologic products for
general symptom management and for coping with the new life situation has tripled to
52% [13]. Thus, healthcare teams should know how to consult patients suffering from
CIPN on complementary treatment options when conventional drugs like Duloxetine or
Gabapentine [14] are not effective enough or when patients’ preference is oriented towards
complementary and integrative health care (CIH).
Previous literature reviews have examined key complementary treatments that can
be applied to relieve general cancer pain [15] or neuropathic pain resulting from drug-
based tumor therapy [16]. The latter systematic review, however, has not included nursing
interventions, like external applications, which are relevant to consider when aiming to
relieve patients’ symptoms and treat them in a holistic and natural way. Even though
Med. Sci. 2023, 11, 15 3 of 34
Brami et al. [16] did suggest applying complementary therapies to prevent or treat CIPN—
for example, Vitamin E, L-Glutamine, Goshajinkigan, and Omega-3—the authors think
that the oral intake of such natural products is not the only option available. In the last
years, there have been other studies published reporting that henna applications [17] or
cryocompression [18,19] are also beneficial, to name just a few more options, and they can
be applied for CIPN symptom management.
Therefore, the purpose of this article is to provide interprofessional healthcare teams
with a comprehensive literature review and clinical recommendations of the best available
evidence on complementary treatments for the prevention of CIPN and for the supportive
management of CIPN during or after conventional treatment.
//dg-pflegewissenschaft.de/sektionen/klinische-pflege/onkologische-pflegeforschung-2/, ac-
cessed on 1 December 2022).
• S = safe;
• CE = clinical experience (rated on a numerical scale 0 to 5, with 0 = no effect and
5 = maximum effect);
• ET = effort of training (education requirements in addition to a nursing grade; 0 = no
additional instructions or education needed, 1 = instructions needed, 2 = application under
guidance, 3 = repeated practice needed, 4 = basic training of rhythmical embrocation (200 h)
recommended but partial skills can be acquired with less than 200 h, and 5 = basic training
of rhythmical embrocation (200 h) needed);
• PF = practical feasibility (PFt = feasibility limited due to time requirements; PFtt = feasibility
strongly limited due to time requirements; PFc = feasibility limited due to high costs
(>30 EUR per month)).
The consensus process is based on the AWMF’s systematic and structured process for
the development of scientific clinical guidelines [34]. It was moderated by two physicians
(DS, PV) and each intervention was evaluated on the above-mentioned criteria. Each
clinic had one vote, and when a clinic was represented by more than one participant, the
participants had to coordinate their vote with each other.
3. Results
3.1. Search Results
A total of 264 potentially relevant articles were identified and screened, wherein
145 articles were assessed in detail, of which 75 studies (41 quantitative studies, 3 mixed-
methods studies, 26 reviews, 5 clinical guidelines) were included in the scoping review
(Figure 1). Most studies were conducted in North America (n = 27), Europe (n = 18), Asia
(n = 16), the Middle East (n = 8), UK (n = 4), and Australia (n = 2).
ing pain with complementary therapies in cancer patients of other patient populations”)
can be found in Appendices 3 and 4). Overall, the study quality ranged from excellent
(n = 29) [15,17,35,37,41,42,45–66] to satisfactory (n = 8) [19,67–73] and poor (n = 1) [74],
while most studies had good study quality (n = 37) [16,18,38–40,43,75–105] (see Table S3 in
Supplementary S5).
Figure 2 illustrates the evidence (Tables S1, S2 and S5) by referring to the number
of studies/expert recommendations that the authors included for the 13 categories of
non-pharmacological treatment options, which can be administered by doctors, oncology
nurses, psycho-oncologists, physiotherapists, and all other members of interprofessional
healthcare teams. Figure 3 visualizes how the different treatment options relate to the
different health professionals. In 38 out of 75 of the studies, statements were made on the
Med. Sci. 2023, 11, x FOR PEER REVIEW 15 of 36
conceptual therapeutic approach. In the following, the evidence for the top seven most
frequently identified complementary procedures are described.
Figure 2. Overview of number of evidence sources for CIPN and general pain.
Figure 2. Overview of number of evidence sources for CIPN and general pain. Legend of Figure 2.
Legend of Figure 2.
− 1 incl. aromatherapy, topical therapy, no oral phytotherapeutics, and flaxseed bath;
−2 incl. physical therapy, sensorimotor training, exercise, closed kinematic chain exer-
− 1 incl. aromatherapy, cise,
topical therapy,
resistance nocardiovascular
training, oral phytotherapeutics, and
exercises, walking, flaxseed
cycling, bath;
whole-body-vi-
− 2 incl. physical therapy,
bration,sensorimotor training,
passive mobilization, exercise,
coordination training,closed kinematic
and tactile stimulation; chain
exercise, resistance− training,
3 incl. relaxation, PMR, yoga, meditation,
cardiovascular exercises,hypnosis,
walking, guided imagery,
cycling, cognitive ther-
whole-body-
apies, and distraction therapy, as well asQi Gong and Tai Chi;
vibration, passive−mobilization, coordination training, and tactile stimulation;
4 incl. vitamin and mineral supplements and dietary modification;
− 3 incl. relaxation, −PMR, yoga,
5 incl. meditation,
alcaline bath and coldhypnosis,
knee and/or guided imagery, cognitive thera-
arm showers;
− therapy,
pies, and distraction 6 incl. Tai Chi, Qi Gong,
as well andGong
as Qi massageandacc. to
TaiTCM;
Chi;
− 7 incl. cryocompression, cold applications, and hypothermia;
− 4 incl. vitamin and −
mineral supplements and dietary modification;
8 incl. hyperthermia;
− 5 incl. alcaline bath
− and cold kneereflexology,
9 incl. massage, and/or arm showers;
and foot reflexology;
− 6 incl. Tai Chi, Qi −Gong, and
10 incl. massage
healing touch, acc.
Reiki,to
andTCM;
therapeutic touch;
− 11 incl. compression, cupping (draining procedures), hydroelectric bath, music ther-
− 7 incl. cryocompression, cold applications, and hypothermia;
apy, support groups, patient education, and nurse-led follow-up.
− 8 incl. hyperthermia;
− Note. Study quality of the included studies varied—see Table S3 (Supplementary S5)
− 9 incl. massage, reflexology,
for criticaland foot reflexology;
appraisal.
− 10 incl. healing touch, Reiki, and therapeutic touch;
− 11 incl. compression, cupping (draining procedures), hydroelectric bath, music ther-
apy, support groups, patient education, and nurse-led follow-up.
− Note. Study quality of the included studies varied—see Table S3 (Supplementary S5)
for critical appraisal.
Med. Sci. 2023, 11, 15 8 of 34
Table 1. Summary of studies and results of consensus process regarding the options (O) for prevention (p) or/and treatment (t) of CIPN.
O for p or t Author 1 Study Design 2 p3 t3 Intervention Outcome Measures Result/Clinical Experience (CE) 4
√ Statistically significant
Noh and Park 2019 [50] RCT (n = 31) - Aroma foot reflexology CIPN assessment tool
reduction of symptoms.
√ Functional Assessment of Cancer Failed to improve the symptoms of
Rostami et al. 2019 [75] RCT (n = 34) - Topical c. colocynthis oil
Therapy (FACT), Neurotoxicity score CIPN compared with placebo.
√ √
Consensus process N/A Aconit oil application Clinical improvement CE 3
√
Consensus process N/A Solum oil application Clinical improvement CE 1
√ √
Consensus process N/A Flaxseed bath Clinical improvement CE 4
√ √
Consensus process N/A Arnica comp/Formica oil application Clinical improvement CE 3
√ Arnica comp/Formica ointment (for
Consensus process N/A - Clinical improvement CE 3–4
stronger effect of Aconit)
√
Consensus process N/A - Rosemary ointment Clinical improvement CE 3–4
√ Peppermint oil application for heat
Consensus process N/A - Clinical improvement CE2
sensations and paraesthesia
√ Eucalyptus oil application for heat
Consensus process N/A - Clinical improvement CE 2
sensations and paraesthesia
Med. Sci. 2023, 11, 15 9 of 34
Table 1. Cont.
O for p or t Author 1 Study Design 2 p3 t3 Intervention Outcome Measures Result/Clinical Experience (CE) 4
Improvement of CIPN pain for
Single-blind ex-ploratory √ √ Patient questionnaires, quantitative patients with breast cancer.
Andersen et al. 2020 [38] Physical therapy
RCT (n = 48) sensory testing Correlation to preservation of
sensory function.
Evidence was reported for
interventions consisting of physical
√ Nerve conduction velocity, (NCV), activity components; for strength and
Systematic review of
Brami et al. 2016 [16] - Physical activity Neurological Symptom Score, Total endurance training; and for
RCTs (n = 13)
Neuropathy Score, QoL multimodal self-help strategies
including physical activity, yoga,
and mindfulness.
Single-group pre-post √
Fernandes and Kumar Modified Total Neuropathy Score Significant change in values before
prospective study - Closed kinematic chain exercise
2016 [69] (mTNS), Berg Balance Score (BBS) and after the exercise.
(n = 25)
Comprehensive
inte-grative √ Empirical evidence is insufficient to
Kanzawa-Lee et al. 2020 Exercise with Aerobic, strength
review(7 RCTs, - CIPN, balance, and fitness definitively conclude that exercise
Movement therapies
Table 1. Cont.
O for p or t Author 1 Study Design 2 p3 t3 Intervention Outcome Measures Result/Clinical Experience (CE) 4
Steinmann et al. 2011 in
√ √ 81% of patients consider tactile
S3 clinical guidelineS3
Overview article Tactile Stimulation (e.g., been bath) Clinical improvement stimulation to be very effective
Guideline Supportive
or effective.
therapy 2020 [37]
Streckmann, Kneis et al.
√ QOL; coordination, Due to the highly significant
2014 in Exercise (sensorimotor training,
RCT (n = 62) - endurance, strength, therapy-induced physiological parameters, the study
S3 Guideline Supportive endurance, strength)
side-effects. was terminated prematurely.
therapy 2020 [37]
Systematic review of √ Number of patients with reduced
Streckmann, Zopf et al.
RCTs (n = 10), CCT - Exercise interventions Side effects of Polyneuropathy deep sensitivity could be diminished.
2014 [60]
(n = 8) Only one RCT related to CIPN.
Sensorimotor training and
Movement therapies
Table 1. Cont.
O for p or t Author 1 Study Design 2 p3 t3 Intervention Outcome Measures Result/Clinical Experience (CE) 4
Comprehensive
Mind-body
therapies
√
Consensus process N/A - Cold knee and/or arm showers Clinical improvement CE 3
Table 1. Cont.
O for p or t Author 1 Study Design 2 p3 t3 Intervention Outcome Measures Result/Clinical Experience (CE) 4
Acupuncture/Acupressure
S3 guideline
complementary √ Data are available from a
BPI, Total Neuropathy Score, NCS,
medicine in the S3 guideline - Acupuncture, electroacupuncture meta-analysis and two RCTs on the
Functional Assessment, QoL.
treatment of oncology efficacy of A- for CIPN.
patients [57]
√ No significant differences in
Neuropathic Pain Symptom
Griffiths et al. 2018 [19] RCT (n = 29) - Frozen glove and sock neuropathy or pain. Drop-out rate,
Inventory, BPI.
more than 50 %.
Prospective pilot study √ Visual analog scale (VAS), No significant difference in NCS. Well
Sundar et al. 2017 [40] - Continuous-flow limb hypothermia.
(n = 20) subjective tolerance scale, NCS, tolerated by all patients.
√
Consensus process N/A - Frozen gloves and socks Clinical improvement Cannot be assessed.
Table 1. Cont.
O for p or t Author 1 Study Design 2 p3 t3 Intervention Outcome Measures Result/Clinical Experience (CE) 4
√
Consensus process N/A - Aconit oil—rhythmical embrocation Clinical improvement CE 4
embrocations
Rhytmical
√ Arnica comp/Formica
Consensus process N/A - Clinical improvement CE 4
oil—rhythmical embrocation
Coyne et al. 2013 [67] - Scrambler therapy Treatment and Cancer CIPN20 significant improvements were seen in
arm trial (n = 39)
(EORTCCIPN20) average, least, and worst pain.
therapy
Figure 3. Interprofessional
Figure CIPNCIPN
3. Interprofessional symptom management.
symptom Legend.
management. Number
Legend. in brackets
Number refer torefer
in brackets ex- to
ternal study evidence and results of the consensus process (Tables S1, S2 and S5).
external study evidence and results of the consensus process (Tables S1, S2 and S5).
Of the five studies with focus on CIPN, three assessed classical M. Classical M signifi-
cantly prevented CIPN and neuropathic pain as well as improved nerve conduction and
QoL when compared to usual care at week 12 (n = 1 study; n = 40 participants receiving ad-
juvant paclitaxel for breast cancer; intervention duration: 12 weeks) [41]. In one case report,
which is also reported in a systematic review [16], classical M is associated with greatly
reduced CIPN symptoms from grade 2 to 1 and markedly improved quality of life [74]. In
one RCT, foot M was shown to reduce patients’ pain scores and have a positive effect on
sleep quality, compared to clinical routine (n = 40 patients with non-Hodgkin’s lymphoma;
intervention duration: four weeks) [76]. A program including M and mobilization as well
as physical E and WBV had a significantly and clinically relevant beneficial impact on
symptom relief, physical fitness, and sensory function (n = 1 study; n = 131 participants;
intervention duration: 15 weeks) [89].
Of the four RCTs that assessed classical M for cancer pain [49,83,87,105], two found
no statistically or clinically improvement in pain (n = 2 studies; n = 610 participants with
cancer pain; intervention duration: two and four weeks) [49,87] and one found significantly
higher reduction of physical discomfort in IG compared to routine health care (n = 1 study;
n = 86 participant; intervention duration: five weeks) [83]. Foot massage showed positive
effects on pain (n = 1 study; n = 87; intervention duration: three consecutive days) [105].
The four RCTs that assessed R in cancer patients [45,46,77,78] reported heterogeneous
effects regarding pain. R was found to have positive effect on pain and overall well-being
compared to aromatherapy-M (n = 1 study, 115 participants, intervention duration: four
treatments) [46]. Reflexology complemented by PMR exercises was found to decrease
pain and fatigue and increase quality of life (n = 1 study; n = 80 participants, intervention
duration: eight weeks) [45]). No statistically significant effect could be shown for pain in
cancer patients treated with foot R (n = 1 study; n = 36 participants; intervention duration:
two times, 24 h apart) [77]. In contrast, an immediate positive effect of foot R for patients
with metastatic cancer who reported pain was found (n = 1 study; n = 256 participants;
intervention duration: four weeks) [78]. Evidence for R as a treatment for any medical
condition could not be demonstrated convincingly in a systematic review (n = 18 RCTs;
n = 949 participants) [72].
In the nine reviews and meta-analyses that assessed M or R in cancer patients [15,
51,56,58,64,99,100,102,103], studies with different types of massage and reflexology were
included. The results were heterogeneous. Improvement of pain through M was reported
(n = 2 studies; n = 30 RCTs; n = 4448 participants) [56,58] as well as through foot reflexology
(n = 1 study; n = 12 RCTs; n = 559 participants) [56]. Weak recommendations are suggested
for M, compared to an active comparator, for the treatment of pain, fatigue, and anxiety.
No recommendations were suggested for M therapy compared to no treatment or sham
control (n = 1 study; n = 16 RCTs) [51]. Beneficial effects of classical M for pain of any origin
are reported in a nursing guideline [66]. Due to the heterogeneous data from RCTs on the
effectiveness of classical M in reducing pain in oncology patients, no recommendation can
be made for or against the use of classical M to reduce pain in another guideline [63].
study [86]. The quality of two studies [15,63] was rated excellent according to the CASP
scheme, and four studies were rated good [81,86,87,104].
According to expert consensus, RE increases the effectiveness of two nursing inter-
ventions for CIPN (Aconit oil, Arnica comp. Formica oil) by one point on the five-point
Likert scale from three to four (Table S4, Supplementary S6). Three RCTs assessed TT or
healing touch (HeTo) in cancer patients. HeTo as well as classical M are more effective
than presence alone or standard care in reducing pain, mood disturbance, and fatigue in
patients receiving cancer chemotherapy (n = 1 study, n = 230 participants, intervention
duration: 4 weeks) [87]. TT led to significantly higher well-being compared to rest period
(n = 1 study; n = 20 participants, intervention duration: 4 consecutive days) [81]. TT
significantly decreased pain and fatigue more than usual care, while the placebo group
indicated a decreasing trend in pain and fatigue scores compared with the usual care group
(n = 1 study; n = 90 participants; intervention duration: 5 days) [104]. One guideline states
that the quality of the included studies [109–111] on TT is too low to provide meaningful
results [63].
HeTo for cancer patients was assessed in one systematic review. HeTo seems promising,
particularly in the short term, but cannot be recommended because of a paucity of rigorous
trials. Future research should focus on methodologically strong RCTs to determine potential
efficacy of these CAM interventions [15]. RE with Solum oil was shown in an observational
study to be a promising and useful complementary method for the treatment of chronic
low back pain [86].
courses) [17]. All types of Phy (e.g., hand/foot bath, compress) used in TCM for reducing
CIPN were assessed in the meta-analysis. Herbs that activate blood, improve micro-
circulation, and dilate collaterals (e.g., astragalus, ginger) were found to have potential
healing effects as well as improvement in sensory nerve conduction velocity (SNCV) and
motor nerve conduction velocity (MNCV). This was found for all grades of CIPN for
preventive and curative treatment, even though more research is needed (n = 20 stud-
ies; n = 1481 participants) [35]. In another review, some types of Phy were found to have
potentially preventive and/or therapeutic effects for CIPN. Due to the characteristics of
CIPN, the direct application would be considered an effective dosage form (n = 28 studies;
n = 2174 participants) [36].
The safety and efficacy of topical Citrullus colocynthis (bitter apple) oil in the manage-
ment of CIPN was evaluated in a RCT. No significant improvement could be shown. The
intervention failed to improve the symptoms of CIPN compared with placebo (n = 1 study;
n = 18 participants, intervention duration: two months) [75]. Solum oil administered as RE
was shown in an observational study to be a promising and useful complementary method
for the treatment of chronic low back pain [86].
tion duration: three times per week for a duration of eight weeks) [84]. CIPN symptoms
improved significantly from pre-E to post-E. Such findings are encouraging and could
be confirmed by a larger trial. Current clinical guidelines for the supportive therapy for
patients with cancer [37] and survivors [98] recommend E therapies as well.
An exercise program including progressive walking (W) and resistance training (RT)
has an effect on patients’ CIPN symptoms [48] (n = 1 study; n = 355 individuals affected with
cancer; intervention duration: six weeks). Compared to the CG, symptoms of hot/coldness
in hands/feet and numbness and tingling were significantly reduced in the IG. This effect
may have developed as exercises can reduce chronic inflammation, and inflammatory pro-
cesses appear to play a role in the etiology and treatment of CIPN. Thus, the authors clearly
call on interprofessional healthcare teams to prescribe exercise therapies for their patients.
A multimodal exercise program including endurance (EN), resistance (RT), and
balance training (BT) on CIPN helped patients to keep their CIPN symptoms stable
(n = 1 study; n = 24 metastasized colorectal cancer patients; intervention duration: two
times per week for 60 min) [94]. Compared to the CG, patients in the IG did not experience
a worsening of their symptoms. Another integrated exercise program including massage
(M), passive mobilization (PM), and physical exercise (E) evaluated whole-body vibration
(WBV) (by applying the vibration platform Galileo-Fitness) (n = 1 study; n = 131 patients
with CIPN; intervention duration: 15 training sessions within 15 weeks) [89]. Patients in
the WBV condition plus the integrated E program performed better with regard to the
primary outcome, the chair-rising test (CRT) (a test where patients are asked to stand up
from a chair and then cross their arms in front of the chest for five times as fast as possible).
All patients completing the study experienced less symptoms and pain and improved their
CRT over time. The authors conclude that this program could be well integrated into daily
clinical practice, but a standardized assessment of CIPN is needed as well as adequate
education of nursing staff. One review assessed WBV [97]. Of the five included studies,
four studies were on diabetic peripheral neuropathy, and one study was on HIV-associated
distal symmetrical polyneuropathy. Three of the five studies found a beneficial effect of
WBV on neuropathic pain as well as for improvements in strength and balance; however,
this was not confirmed by two others of the included studies. As the methodology for all
included studies was reported to be low, and none was focused on patients with cancer
or survivors, the authors conclude that there is a high need to further explore the effect of
WBV in high-quality trials in cancer populations.
Those encouraging results and recommendations, however, have been dimmed by
some reviews including a range of studies investigating if MT contribute to CIPN and
pain relief. One current review synthesized evidence for the effects of exercise on CIPN
symptoms [54], and only clinical trials and meta-analyses have been searched, so that the
results yielded in 13 included studies investigating four different types of exercise (E): Yoga
(Y), aerobic (Ae) E, strength training (STr), and balance training (BT). It was concluded
that none of the studies met 100% of the CONSORT checklist criteria, and only two of the
studies were considered as moderate-quality evidence. Even though all the seven studies
demonstrated that AeE led to significant CIPN benefits, the authors recommended inter-
preting the results with caution and suggested that more evidence is needed to conclude
that E interventions influence CIPN symptoms. Nevertheless, healthcare professionals
including oncologists, oncology nurses, psycho-oncologists, nutritional therapists, physio-
therapist, and pharmacists can inform and encourage patients and survivors of practicing
physical E to improve their balance, fitness, and better manage their symptomatic burden.
The authors of a Cochrane review [57], which already dates back several years, came to
a similar conclusion, and due to a large heterogeneity of included E programs (40 trials
on STr, resistance training (RT), walking (W), cycling (Cy), Y, QG, and TC), it was difficult
to draw concrete conclusion and recommendations. In a systematic review of systematic
reviews [64], effects of multiple rehabilitation interventions, including E and physical
activity (PhA), complementary and alternative medicine, Y, lymphoedema treatment, and
psychosocial interventions, could be demonstrated for general pain and other symptom
Med. Sci. 2023, 11, 15 20 of 34
outcomes. Here again, the effect concepts have not been differentiated. All 37 included
studies were evaluated with the AMSTAR 2 tool, with 21 were having low, 14 having mod-
erate, and 2 having high methodological quality. In other reviews, however, the general
benefits of non-pharmacological interventions including physical therapy (PT) to reduce
CIPN [102] and general pain [100] have been pointed out and are more comprehensible
due to the applied categorization system.
One review assessed strength- and balance-training (STr and BT) programs in pa-
tients at high risk of falls [96]. Overall, 3 out of 13 studies found that Str and BT were
safe and effective at reducing falls and improving strength and balance in adult patients
with diabetes-related peripheral neuropathy. Future research could use this as a basis to
conduct further studies with these safe and effective interventions for cancer patients with
CIPN. One clinical guideline assessed preventative options for CIPN [37]. Regular MT, in
particular for training the fingers and toes, as well as sensorimotor training (SMT) with
bean baths, or electrotherapy with two- or four-cell baths (here one or two extremities—
feet/lower legs or hands/forearms—are immersed in a water bath and a larger plate
electrode—200 to 300 cm2 —is placed lumbar or cervical, respectively) have been presented
as non-pharmacological options for preventing CIPN. Tactile stimulation by application
of special naturopathic procedures, such as beeswax kneading, hedgehog ball massage,
and quartz sand baths, has also been recommended by the expert panel based on yearlong
experience as options for early prevention and/or treatment of CIPN.
3.9.1. Yoga
Yoga (Y) is an ancient Indian system focusing on the physical, mental, and spiritual
practices with the aim to calm one’s thoughts and belief concepts. Thus, Y has a strong
meditative component that also includes pranayamas, or breathing techniques.
An intervention consisting of somatic Yoga (Y) and meditation (Me) improved QoL,
flexibility, and balance (n = 1 study; n = 10 participants with cancer survivors suffering of
CIPN; intervention duration: twice a week for eight weeks for 1.5 h) [80]. Two systematic
Med. Sci. 2023, 11, 15 21 of 34
reviews assessed MBT. Furthermore, 1 of 13 RCTs in one systematic review [16] found MBT
including self-management strategies like Y and Me to reduce CIPN symptoms. Another
systematic review including seven RCTs and six quasi-experiments [54] recommended
balance training including Y as promising preventive interventions and treatments for
CIPN. Additionally, 16 studies assessed MBT for other pain and patient-reported outcomes.
Y sessions improved psychological distress as well as fatigue, nausea and vomiting, pain,
shortness of breath, insomnia, loss of appetite, and constipation compared to a CG at week
6 (n = 1 study; n = 40 breast cancer patients receiving adjuvant radiotherapy; intervention
duration: three Y per week for six weeks) [92]. Two systematic reviews focused on Y
practices. In nine RCTs, Y was compared with a CG and was found to significantly reduce
distress, anxiety, depression, and moderately reduce fatigue, as well as moderately increase
general HRQoL, emotional function, and social function in patients with breast cancer [52].
However, studies lacked long intervention durations; only two studies lasted 12 weeks
or longer, all others were shorter and ranged from 6 to 10 weeks. Another systematic
review of systematic reviews [64] recommended Y for treating anxiety during active cancer
treatment and for improving fatigue, sleep disturbances, gastrointestinal symptoms, and
depression. The practice of Y was recommended for at least 3 months. Another Cochrane
review assessed exercise interventions including Y on HRQoL and associated outcomes
in cancer survivors [57]. The totality of the movement interventions had an effect on
HRQoL at 12 weeks and 6 months follow-up compared to a CG. Exercise interventions also
reduced anxiety at 12 weeks follow-up, fatigue at 12 weeks and between 12 weeks and 6
months follow-up, and pain at 12 weeks follow-up compared to a CG. In another review
educational article, Y was also recommended for patients with spinal cord injury (SCI)
suffering of neuropathic pain (NP) [73]. Even though the pathogenesis of SCI induced NP
is different compared to CIPN, the evidence shows that Y has also the potential to alleviate
other pain types.
Problem-Solving Therapies
Problem-solving therapy (PST) significantly reduced symptom limitations including
pain when compared to a CG (n = 1 study; n = 237 individuals affected with cancer;
intervention duration: 18-week cognitive behavioral intervention with 10 contacts) from
week 10 onwards [79].
The literature search yielded three results related to CIPN [65,67,71] and four to cancer
pain [66,98,100,102]. Within these studies, two systematic reviews [100,102], three four-arm
RCTs [65,67,71] and two guidelines [66,98] were included. The quality of two studies was
rated as excellent according to the CASP scheme [65,66], three studies as good [98,100,102],
and two as satisfactory [67,71]. Further details on the assessment of study quality according
to the CASP scheme can be found in Supplementary S5 (Table S3).
3.11.1. TENS
A wireless, patient-controlled TENS unit significantly improved CIPN and associ-
ated outcomes (numeric rating scale of pain, tingling, numbness, and cramping) after
patients’ completion of chemotherapy (n = 1 study; n = 26 patients with CIPN symptoms;
intervention duration: 2–6 h per day stimulation for 6 weeks).
Two systematic reviews assessed TENS. One of the included studies in an educational
review on CIPN describes the physical effects resulting of TENS: increase of endorphin
release and block noxious sensory impulses trough distraction, strongly supporting that
physical therapists may administer TENS [102]. One of eleven studies in one systematic
review [100] found TENS to have the potential to reduce cancer bone pain. One expert
standard discussed TENS for pain management with the conclusion that there is currently
not enough evidence of TENS efficacy for adults with neuropathic pain [66]. One clinical
guideline on cancer survivorship recommended TENS as well as ST as non-pharmacological
treatment options for general cancer pain, pointing out that oncologists might refer to such
therapy options when addressing patients’ needs in consultations [98].
events in patients with back pain [52]. Otherwise, Y can be considered as a safe mind–body
intervention and can in particular be recommended to patients for improving their quality
of life as well as their mental health status [124]. Adverse events for cupping (C) are rare as
well, but there have been three cases of fainting (vaso-vagal syncope) reported with wet
C [55]. No recommendation can be made for Acetyl-l-carnitine (AlC), as this supplement
may worsen CIPN [16,42,63,125].
4. Discussion
This two-phase approach with a systematic scoping review and a structured consensus
process aimed to provide interprofessional healthcare teams with a comprehensive review
and recommendations for clinical practice of the best available evidence on complementary
treatments for the supportive management of CIPN. In total, 13 non-pharmacological
interventions were identified. The evidence of the scoping review showed that patients with
cancer may benefit from treatments that healthcare providers practice or recommend for
patients like massage (M), reflexology (R), therapeutic touch (TT), rhythmical embrocations
(REH), or aromatherapy (AT) or AT-M. One advantage of complementary treatments is
that patients may practice, after a short briefing and education session, those therapies by
themselves, like movement therapies (MT) ranging from cardiovascular exercises (CardE)
to walking (W), as well as mind–body therapies (MBT) like meditation (Me), Yoga (Y), or
relaxation (Rel) techniques. Interprofessional healthcare teams, however, should be aware
that each potential intervention should be carefully considered regarding its external study
evidence and its study quality, as well as the individual patients’ needs and preferences
and their possibly prior experiences with complementary therapies.
The recommendations by the integrative oncology expert panel (Tables 1, S1 and S5)
demonstrated a highly consistent benefit in preventing or relieving CIPN symptoms pa-
tients with cancer can experience when using complementary treatments by nursing in-
terventions in the form of phytotherapeutic (Phy) interventions, cryotherapy (CT), hy-
drotherapy (HTK), and tactile stimulation (TS). Additional supportive interventions are
presented in Table S2 of the scoping review. Here, the authors aimed to match the expert
recommendations from practice with external study evidence and wanted to highlight
even more treatment possibilities. In total, we could include 16 studies with different study
designs to demonstrate that there is incipient nascent evidence for different nursing inter-
ventions in the context of CIPN symptom management. The effects for henna application
(HA), cryocompression (CC), frozen gloves (FG), cryotherapy (CT), classical massage (M),
foot massage (FM), foot reflexology (FR), reflexology (R), and herbal medicines (Phy) and
sensorimotor training (SM) are encouraging and have been presented as possible further
complementary treatment options. Previous reviews [15,18] or clinical guidelines [42,63]
have not been able to clearly point out such recommendations, probably due to their publi-
cation date or because they only considered RCTs, and non-RCTs were left out for a reason
due to quality/risk of bias concerns. Thus, the authors think that the above mentioned
non-pharmacological interventions are priority areas for future rigorous RCTs to confirm
efficacy prior to being routinely recommended to patients.
With the help of a scoping review methodology, the authors were able to also include
studies with a non-RCT study design and pilot studies, as well as studies with a quasi-
experimental design, case reports, or controlled studies, to point out a comprehensive
map of treatments that are available and might help in individual patients. Of course, the
presented therapy options cannot be applied with a “watering can principle” or a “one-size-
fits-all” approach. According to the EbM approach, the choice of intervention is selected
in consideration of the patient’s perspective and the individual clinical expertise of the
health professionals [22]. For all presented complementary treatments, appropriate training
is necessary, and a precise understanding of the interventions as well as the indications
and contraindications is an important precondition before applying those interventions
in everyday care. As a first step into the field of complementary therapies, interested
healthcare professionals can find an overview of effective therapies here, but the second
Med. Sci. 2023, 11, 15 25 of 34
step needs to be a comprehensive training in such therapies to precisely get to know which
patients can benefit from which complementary therapies in which situations.
Ayurvedic medicine in the case of Y or TCM in the case of QG and TC), as the effect concept
is different compared to classical MT like AeT or RT. Future research on CIPN interventions
might focus more on patient-reported outcomes measures (PROMs) and validated grading
systems for neuropathy in the first instance, so that patient-oriented outcomes (PROs) can
be measured and compared within and between the studies. Such data are also relevant for
clinical consultations in which healthcare professionals can then better address the current
needs and demands of their patients.
nor clinical guidelines focusing on recommendations for action in this field, it is even more
important to make the practical experience of the many years of experiential knowledge of
oncology nurses visible and applicable to other clinics and nurses. Stolz et al. [20] reported
on a systematic methodology combining both evidence types with which it is possible
to generate clinical recommendations. Following this approach, the authors were able to
comprehensively overview all possible complementary therapy options for CIPN manage-
ment, thereby considering the field from an interprofessional perspective; thus, the authors
could present in detail which therapies can be conducted by which healthcare professionals
(Figure 3). Future research may be especially recommended for cryotherapy interventions,
however, only for cryocompression and continuous-flow hypothermia [18,40]. In contrast
to the high drop-out rates up to 50% for cryotherapy with frozen gloves [19], cryocompres-
sion and continuous-flow hypothermia [18,40] were safe and well-tolerated interventions
to prevent CIPN and should be investigated in a larger trial.
For future intervention research, the authors strongly recommend including a qualitative–
quantitative process analysis running parallel to the main outcome study, so that it is
possible to (1) include the perspective of the patients and the health professionals and
(2) consider context and individual aspects that cannot be measured with quantitative
data [135]. Another important aspect for future supportive care research, especially in
the area of CIPN, is to include more patient-reported outcomes measures (PROMs, which
are experienced by patients in everyday life) and patient-reported experience measures
(PREMs, like patient satisfaction with conventional and complementary treatment), so that
patient care interventions can be assessed in a validated and reliable way.
for considering applying such complementary therapies in routine care and treatment is
provided. The authors decided to appraise the quality of the studies, as it is common with
systematic reviews and increasingly with scoping reviews, by applying CASP [33] to have
a better insight into the quality of the included studies and to know if some studies need to
be excluded. The CASP appraisal form was, however, not always suitable for the different
studies considered. As there were no appraisal forms available, for example for case reports
or retrospective studies, those were appraised with the CASP-RCT form, even though not
all questions (in particular questions 4–7) were applicable. The rating would therefore have
been different with other appraisal tools.
5. Conclusions
The best available evidence of non-pharmacological treatments for CIPN management
in patients with cancer are summarized herein. Based on the literature and the long-
term practical experience of the involved experts, the interventions shown here have
high potential to be widely implemented into routine care. For complementary methods
for CIPN to be implemented into safe and evidence-based practice, healthcare providers
would need to expand clinical practice with additional training. Patients would need
more information that empowers them to actively ask their healthcare team for these
treatments more often. To support this, future research in symptom care and treatment
would be useful to make the expert knowledge “tangible”. Future prospective trials are
also needed to validate the efficacy and safety of the here presented non-pharmacological
interventions in individuals affected with cancer, so targeted interventions can be developed
and implemented to treat and prevent the symptoms of complex CIPN.
References
1. Hou, S.; Huh, B.; Kim, H.K.; Kim, K.-H.; Abdi, S. Treatment of Chemotherapy-Induced Peripheral Neuropathy: Systematic
Review and Recommendations. Pain Physician 2018, 21, 571–592. [PubMed]
2. Colvin, L.A. Chemotherapy-induced peripheral neuropathy: Where are we now? Pain 2019, 160 (Suppl. 1), S1–S10. [CrossRef]
[PubMed]
3. Areti, A.; Yerra, V.G.; Komirishetty, P.; Kumar, A. Potential Therapeutic Benefits of Maintaining Mitochondrial Health in Peripheral
Neuropathies. Curr. Neuropharmacol. 2016, 14, 593–609. [CrossRef]
4. Kolb, N.A.; Smith, A.G.; Singleton, J.R.; Beck, S.L.; Stoddard, G.J.; Brown, S.; Mooney, K. The Association of Chemotherapy-
Induced Peripheral Neuropathy Symptoms and the Risk of Falling. JAMA Neurol. 2016, 73, 860–866. [CrossRef] [PubMed]
5. Molassiotis, A.; Cheng, H.L.; Lopez, V.; Au, J.S.K.; Chan, A.; Bandla, A.; Leung, K.T.; Li, Y.C.; Wong, K.H.; Suen, L.K.P.; et al. Are
we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective,
multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 2019, 19, 132. [CrossRef]
[PubMed]
6. Staff, N.P.; Grisold, A.; Grisold, W.; Windebank, A.J. Chemotherapy-induced peripheral neuropathy: A current review. Ann.
Neurol. 2017, 81, 772–781. [CrossRef] [PubMed]
7. Bandos, H.; Melnikow, J.; Rivera, D.R.; Swain, S.M.; Sturtz, K.; Fehrenbacher, L.; Wade, J.L.; Brufsky, A.M.; Julian, T.B.;
Margolese, R.G.; et al. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated with Adjuvant Chemotherapy: NRG
Oncology/NSABP B-30. J. Natl. Cancer Inst. 2018, 110, djx162. [CrossRef]
8. Zajaczkowska,
˛ R.; Kocot-K˛epska, M.; Leppert, W.; Wrzosek, A.; Mika, J.; Wordliczek, J. Mechanisms of Chemotherapy-Induced
Peripheral Neuropathy. Int. J. Mol. Sci. 2019, 20, 1451. [CrossRef]
9. Smith, E.M.L.; Pang, H.; Cirrincione, C.; Fleishman, S.; Paskett, E.D.; Ahles, T.; Bressler, L.R.; Fadul, C.E.; Knox, C.; Le-Lindqwister,
N.; et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral
neuropathy: A randomized clinical trial. JAMA 2013, 309, 1359–1367. [CrossRef]
10. Hershman, D.L.; Lacchetti, C.; Dworkin, R.H.; Smith, E.M.L.; Bleeker, J.; Cavaletti, G.; Chauhan, C.; Gavin, P.; Lavino, A.; Lustberg,
M.B.; et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American
Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 2014, 32, 1941–1967. [CrossRef]
11. Boon, H.S.; Olatunde, F.; Zick, S.M. Trends in complementary/alternative medicine use by breast cancer survivors: Comparing
survey data from 1998 and 2005. BMC Womens Health 2007, 7, 4. [CrossRef] [PubMed]
12. Keene, M.R.; Heslop, I.M.; Sabesan, S.S.; Glass, B.D. Complementary and alternative medicine use in cancer: A systematic review.
Complement. Ther. Clin. Pract. 2019, 35, 33–47. [CrossRef]
13. Buckner, C.A.; Lafrenie, R.; Dénommée, J.A.; Caswell, J.M.; Want, D.A. Complementary and alternative medicine use in patients
before and after a cancer diagnosis. Curr. Oncol. 2018, 25, e275–e281. [CrossRef] [PubMed]
14. Teoh, D.; Smith, T.J.; Song, M.; Spirtos, N.M. Care After Chemotherapy: Peripheral Neuropathy, Cannabis for Symptom Control,
and Mindfulness. Am. Soc. Clin. Oncol. Educ. Book 2018, 38, 469–479. [CrossRef]
15. Bardia, A.; Barton, D.L.; Prokop, L.J.; Bauer, B.A.; Moynihan, T.J. Efficacy of complementary and alternative medicine therapies in
relieving cancer pain: A systematic review. J. Clin. Oncol. 2006, 24, 5457–5464. [CrossRef] [PubMed]
16. Brami, C.; Bao, T.; Deng, G. Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A
systematic review. Crit. Rev. Oncol. Hematol. 2016, 98, 325–334. [CrossRef]
17. Arslan, S.; Bahceli, P.Z.; Ilik, Y.; Artaç, M. The preliminary effects of henna on chemotherapy-induced peripheral neuropathy in
women receiving oxaliplatin-based treatment: A parallel-group, randomized, controlled pilot trial. Eur. J. Oncol. Nurs. 2020,
48, 101827. [CrossRef]
18. Bandla, A.; Tan, S.; Kumarakulasinghe, N.B.; Huang, Y.; Ang, S.; Magarajah, G.; Hairom, Z.; Lim, J.S.J.; Wong, A.; Chan, G.; et al.
Safety and tolerability of cryocompression as a method of enhanced limb hypothermia to reduce taxane-induced peripheral
neuropathy. Support. Care Cancer 2020, 28, 3691–3699. [CrossRef]
19. Griffiths, C.; Kwon, N.; Beaumont, J.L.; Paice, J.A. Cold therapy to prevent paclitaxel-induced peripheral neuropathy. Support.
Care Cancer 2018, 26, 3461–3469. [CrossRef]
20. Stolz, R.; Klafke, N.; Kröger, B.; Boltenhagen, U.; Kaltenbach, A.; Heine, R.; Idler, C.; Layer, M.; Kohler, S.; Winkler, M. Creating
evidence for naturopathic nursing interventions in oncology—A systematic approach. Z Evid. Fortbild. Qual. Gesundhwes. 2021,
166, 1–7. [CrossRef]
21. Steinmann, D.; Babadağ Savaş, B.; Felber, S.; Joy, S.; Mertens, I.; Cramer, H.; Paul, A.; Layer, M.; Klafke, N.; Stolz, R. Nursing
Procedures for the Prevention and Treatment of Mucositis Induced by Cancer Therapies: Clinical Practice Guideline Based on
an Interdisciplinary Consensus Process and a Systematic Literature Search. Integr. Cancer Ther. 2021, 20, 1534735420940412.
[CrossRef] [PubMed]
22. Sackett, D.L.; Rosenberg, W.; Gray, J.A.M.; Haynes, R.B.; Richardson, W.S. Evidence based medicine: What it is and what it isn’t.
BMJ 1996, 312, 71–72. [CrossRef] [PubMed]
23. CEBM. Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March 2009). Available online: https://www.cebm.ox.
ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 (accessed on
18 July 2022).
Med. Sci. 2023, 11, 15 30 of 34
24. Assaf, C.; Booken, N.; Dippel, E.; Guenova, E.; Jonak, C.; Klemke, C.D.; Nicolay, J.P.; Schlaak, M.; Wobser, M.; Trautinger, F.
Chlormethin-Gel zur Behandlung der Mycosis fungoides: Ein Expertenkonsens aus Deutschland, Österreich und der Schweiz
(DACH-Region) zum Therapiemanagement. J. Dtsch. Dermatol. Ges. 2022, 20, 579–588. [CrossRef] [PubMed]
25. Tricco, A.C.; Lillie, E.; Zarin, W.; O’Brien, K.K.; Colquhoun, H.; Levac, D.; Moher, D.; Peters, M.D.; Horsley, T.; Weeks, L. PRISMA
Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann. Intern. Med. 2018, 169, 467–473. [CrossRef]
26. Arksey, H.; O’Malley, L. Scoping studies: Towards a methodological framework. Int. J. Soc. Res. Methodol. 2005, 8, 19–32.
[CrossRef]
27. Levac, D.; Colquhoun, H.; O’Brien, K.K. Scoping studies: Advancing the methodology. Implement. Sci. 2010, 5, 69. [CrossRef]
28. Peters, M.; Godfrey, C.; McInerney, P.; Munn, Z.; Tricco, A.C.; Khalil, H. Chapter 11: Scoping Reviews (2020 Version). In
JBI Manual for Evidence Synthesis; Aromataris, E., Munn, Z., Eds.; JBI: Adelaide, Australia, 2020; Available online: https:
//synthesismanual.jbi.global (accessed on 18 July 2022).
29. National Center for Complementary and Integrative Health. Complementary, Alternative, or Integrative Health: What’s in a
Name? 2021. Available online: https://www.nccih.nih.gov/health/complementary-alternative-or-integrative-health-whats-
in-a-name (accessed on 4 November 2022).
30. Witt, C.M.; Balneaves, L.G.; Cardoso, M.J.; Cohen, L.; Greenlee, H.; Johnstone, P.; Kücük, .; Mailman, J.; Mao, J.J. A Comprehensive
Definition for Integrative Oncology. J. Natl. Cancer Inst. Monogr. 2017, 2017, lgx012. [CrossRef]
31. Stolz, R.; Klafke, N. Complementary Nursing Procedures to Treat Polyneuropathy in Cancer Patients Undergoing Chemother-
apy. 2020. Available online: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020165851 (accessed on
2 February 2020).
32. Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. Syst. Rev.
2016, 5, 210. [CrossRef]
33. Critical Appraisal Skills Programme. CASP (Randomised Controlled Trials Checklist, Systematic Review Checklist, Qualitative
Studies Checklist, Cohort Study Checklist). 2019. Available online: https://casp-uk.net/casp-tools-checklists/ (accessed on
18 July 2022).
34. AWMF. AWMF-Regelwerk Leitlinien: Strukturierte Konsensfindung. 2022. Available online: https://www.awmf.org/
leitlinien/awmf-regelwerk/leitlinien-entwicklung/awmf-regelwerk-03-leitlinienentwicklung/ll-entwicklung-strukturierte-
konsensfindung.html (accessed on 18 July 2022).
35. Li, Z.; Jin, H.; Yan, Q.; Sun, L.; Wasan, H.S.; Shen, M.; Ruan, S. The Method of Activating Blood and Dredging Collaterals for
Reducing Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Evid. Based Complement.
Alternat. Med. 2019, 2019, 1029626. [CrossRef]
36. Noh, H.; Yoon, S.; Park, B. A Systematic Review of Herbal Medicine for Chemotherapy Induced Peripheral Neuropathy. Evid.
Based Complement. Alternat. Med. 2018, 2018, 6194184. [CrossRef]
37. AWMF. Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V.
(AWMF), Deutschen Krebsgesellschaft e.V. (DKG) und Deutschen Krebshilfe (DKH). Supportive Therapie bei onkologischen
PatientInnen—Langversion 1.3. 2020. Available online: https://register.awmf.org/assets/guidelines/032-054OLl_S3_Supportiv_
2020-07-abgelaufen.pdf (accessed on 22 December 2022).
38. Andersen Hammond, E.; Pitz, M.; Steinfeld, K.; Lambert, P.; Shay, B. An Exploratory Randomized Trial of Physical Therapy for
the Treatment of Chemotherapy-Induced Peripheral Neuropathy. Neurorehabilit. Neural Repair 2020, 34, 235–246. [CrossRef]
39. Beijers, A.; Bonhof, C.; Mols, F.; Ophorst, J.; de Vos-Geelen, J.; Jacobs, E.; van de Poll-Franse, L.; Vreugdenhil, G. Multicenter
randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced
peripheral neuropathy. Ann. Oncol. 2020, 31, 131–136. [CrossRef] [PubMed]
40. Sundar, R.; Bandla, A.; Tan, S.S.H.; Liao, L.-D.; Kumarakulasinghe, N.B.; Jeyasekharan, A.D.; Ow, S.G.W.; Ho, J.; Tan, D.S.P.; Lim,
J.S.J.; et al. Limb hypothermia for preventing paclitaxel-induced peripheral neuropathy in breast cancer patients: A pilot study.
Front. Oncol. 2017, 6, 274. [CrossRef] [PubMed]
41. Izgu, N.; Metin, Z.G.; Karadas, C.; Ozdemir, L.; Çetin, N.; Demirci, U. Prevention of chemotherapy-induced peripheral neuropathy
with classical massage in breast cancer patients receiving paclitaxel: An assessor-blinded randomized controlled trial. Eur. J.
Oncol. Nurs. 2019, 40, 36–43. [CrossRef] [PubMed]
42. Greenlee, H.; DuPont-Reyes, M.J.; Rn, L.G.B.; Carlson, L.E.; Cohen, M.R.; Deng, G.; Johnson, J.A.; Mumber, M.; Seely, D.; Zick,
S.M.; et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment.
CA A Cancer J. Clin. 2017, 67, 194–232. [CrossRef] [PubMed]
43. Kotani, H.; Terada, M.; Mori, M.; Horisawa, N.; Sugino, K.; Kataoka, A.; Adachi, Y.; Gondou, N.; Yoshimura, A.; Hattori, M.;
et al. Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: Results from a
double-blind phase 2 trial. BMC Cancer 2021, 21, 548. [CrossRef] [PubMed]
44. Volger, E.; Brinkhaus, B. Einteilung der Naturheilverfahren. In Kursbuch Naturheilverfahren für die Ärztliche Weiterbildung; Volger,
E., Brinkhaus, B., Eds.; Urban & Fischer: Munich, Germany, 2017; pp. 5–6.
45. Dikmen, H.A.; Terzioglu, F. Effects of reflexology and progressive muscle relaxation on pain, fatigue, and quality of life during
chemotherapy in gynecologic cancer patients. Pain Manag. Nurs. 2019, 20, 47–53. [CrossRef]
46. Dyer, J.; Thomas, K.; Sandsund, C.; Shaw, C. Is reflexology as effective as aromatherapy massage for symptom relief in an adult
outpatient oncology population? Complement. Ther. Clin. Pract. 2013, 19, 139–146. [CrossRef]
Med. Sci. 2023, 11, 15 31 of 34
47. Gok Metin, Z.; Arikan Donmez, A.; Izgu, N.; Ozdemir, L.; Arslan, I.E. Aromatherapy massage for neuropathic pain and quality of
life in diabetic patients. J. Nurs. Scholarsh. 2017, 49, 379–388. [CrossRef]
48. Kleckner, I.R.; Kamen, C.; Gewandter, J.S.; Mohile, N.A.; Heckler, C.E.; Culakova, E.; Fung, C.; Janelsins, M.C.; Asare, M.; Lin, P.-J.
Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: A multicenter, randomized controlled
trial. Support. Care Cancer 2018, 26, 1019–1028. [CrossRef]
49. Kutner, J.S.; Smith, M.C.; Corbin, L.; Hemphill, L.; Benton, K.; Mellis, B.K.; Beaty, B.; Felton, S.; Yamashita, T.E.; Bryant, L.L.
Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer [with consumer summary].
Ann. Intern. Med. 2008, 149, 369–379. [CrossRef] [PubMed]
50. Noh, G.O.; Park, K.S. Effects of aroma self-foot reflexology on peripheral neuropathy, peripheral skin temperature, anxiety, and
depression in gynaecologic cancer patients undergoing chemotherapy: A randomised controlled trial. Eur. J. Oncol. Nurs. 2019,
42, 82–89. [CrossRef] [PubMed]
51. Boyd, C.; Crawford, C.; Paat, C.F.; Price, A.; Xenakis, L.; Zhang, W.; Group, E.f.M.T.W. The impact of massage therapy on function
in pain populations—A systematic review and meta-analysis of randomized controlled trials: Part II, cancer pain populations.
Pain Med. 2016, 17, 1553–1568. [CrossRef]
52. Buffart, L.M.; Van Uffelen, J.G.Z.; I Riphagen, I.; Brug, J.; Van Mechelen, W.; Brown, W.J.; Chinapaw, M.J.M. Physical and
psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled
trials. BMC Cancer 2012, 12, 559. [CrossRef]
53. Deng, G.E.; Rausch, S.M.; Jones, L.W.; Gulati, A.; Kumar, N.B.; Greenlee, H.; Pietanza, M.C.; Cassileth, B.R. Complementary
therapies and integrative medicine in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest
Physicians evidence-based clinical practice guidelines. Chest 2013, 143 (Suppl. 5), e420S–e436S. [CrossRef] [PubMed]
54. Kanzawa-Lee, G.A.; Larson, J.L.; Resnicow, K.; Smith, E.M.L. Exercise Effects on Chemotherapy-Induced Peripheral Neuropathy:
A Comprehensive Integrative Review. Cancer Nurs. 2020, 43, E172–E185. [CrossRef]
55. Kim, J.-I.; Lee, M.S.; Lee, D.-H.; Boddy, K.; Ernst, E. Cupping for treating pain: A systematic review. Evid. Based Complement.
Altern. Med. 2011, 2011, 467014. [CrossRef]
56. Lee, S.-H.; Kim, J.-Y.; Jong-Yeop, K.; Kim, S.; Lim, S. Meta-analysis of massage therapy on cancer pain. Integr. Cancer Ther. 2015,
14, 297–304. [CrossRef]
57. Mishra, S.I.; Scherer, R.W.; Snyder, C.; Geigle, P.M.; Berlanstein, D.; Topaloglu, O. Exercise interventions on health-related quality
of life for cancer survivors (Cochrane review) [with consumer summary]. Cochrane Database Syst. Rev. 2012, 8, CD007566.
58. Pan, Y.Q.; Yang, K.H.; Wang, Y.L.; Zhang, L.P.; Liang, H.Q. Massage interventions and treatment-related side effects of breast
cancer: A systematic review and meta-analysis. Int. J. Clin. Oncol. 2013, 19, 829–841. [CrossRef]
59. Stier-Jarmer, M.; Throner, V.; Kirschneck, M.; Frisch, D.; Schuh, A. Effekte der Kneipp-Therapie: Ein systematischer Review der
aktuellen wissenschaftlichen Erkenntnisse (2000–2019). Complement. Med. Res. 2021, 28, 146–159. [CrossRef]
60. Streckmann, F.; Zopf, E.M.; Lehmann, H.C.; May, K.; Rizza, J.; Zimmer, P.; Gollhofer, A.; Bloch, W.; Baumann, F.T. Exercise
intervention studies in patients with peripheral neuropathy: A systematic review. Sports Med. 2014, 44, 1289–1304. [CrossRef]
[PubMed]
61. Van Vu, D.; Molassiotis, A.; Ching, S.S.Y.; Le, T.T. Effects of Qigong on symptom management in cancer patients: A systematic
review. Complement. Ther. Clin. Pract. 2017, 29, 111–121. [CrossRef] [PubMed]
62. Wayne, P.M.; Lee, M.; Novakowski, J.; Osypiuk, K.; Ligibel, J.; Carlson, L.; Song, R. Tai Chi and Qigong for cancer-related
symptoms and quality of life: A systematic review and meta-analysis. J. Cancer Surviv. 2018, 12, 256–267. [CrossRef] [PubMed]
63. AWMF. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Komplementärmedizin
in der Behandlung von onkologischen PatientInnen, Langversion 1.1. Available online: https://www.leitlinienprogramm-
onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Komplement%C3%A4r/Version_1/LL_Komplement%C3%A4
r_Langversion_1.0.pdf (accessed on 22 December 2022).
64. Möller, U.O.; Beck, I.; Rydén, L.; Malmström, M. A comprehensive approach to rehabilitation interventions following breast
cancer treatment—A systematic review of systematic reviews. BMC Cancer 2019, 19, 472.
65. Gewandter, J.S.; Chaudari, J.; Ibegbu, C.; Kitt, R.; Serventi, J.; Burke, J.; Culakova, E.; Kolb, N.; Sluka, K.A.; Tejani, M.A.; et al.
Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: An open-label
feasibility study. Support. Care Cancer 2019, 27, 1765–1774. [CrossRef] [PubMed]
66. Deutsches Netzwerk für Qualitätsentwicklung in der Pflege (DNQP). Expertenstandard Schmerzmanagement in der Pflege. In
Schriftenreihe des Deutschen Netzwerks für Qualitätsentwicklung in der Pflege; DNQP: Osnabrück, Germany, 2020.
67. Coyne, P.J.; Wan, W.; Dodson, P.; Swainey, C.; Smith, T.J. A Trial of Scrambler Therapy in the Treatment of Cancer Pain Syndromes
and Chronic Chemotherapy-Induced Peripheral Neuropathy. J. Pain Palliat. Care Pharmacother. 2013, 27, 359–364. [CrossRef]
[PubMed]
68. Donald, G.K.; Tobin, I.; Stringer, J. Evaluation of acupuncture in the management of chemotherapy-induced peripheral neuropathy.
Acupunct. Med. 2011, 29, 230–233. [CrossRef]
69. Fernandes, J.; Kumar, S. Effect of lower limb closed kinematic chain exercises on balance in patients with chemotherapy-induced
peripheral neuropathy: A pilot study. Int. J. Rehabil. Res. 2016, 39, 368–371. [CrossRef]
70. Kwekkeboom, K.L. Pain management strategies used by patients with breast and gynecologic cancer with postoperative pain.
Cancer Nurs. 2001, 24, 378–386. [CrossRef]
Med. Sci. 2023, 11, 15 32 of 34
71. Loprinzi, C.; Le-Rademacher, J.G.; Majithia, N.; McMurray, R.P.; O’Neill, C.R.; Bendel, M.A.; Beutler, A.; Lachance, D.H.; Cheville,
A.; Strick, D.M.; et al. Scrambler therapy for chemotherapy neuropathy: A randomized phase II pilot trial. Support. Care Cancer
2020, 28, 1183–1197. [CrossRef] [PubMed]
72. Ernst, E. Is reflexology an effective intervention? A systematic review of randomised controlled trials. Med. J. Aust. 2009, 191,
263–266. [CrossRef] [PubMed]
73. Telles, S.; Sayal, N.; Nacht, C.; Chopra, A.; Patel, K.; Wnuk, A.; Dalvi, P.; Bhatia, K.; Miranpuri, G.; Anand, A. Yoga: Can it be
integrated with treatment of neuropathic pain? Ann. Neurosci. 2019, 26, 82–91. [CrossRef] [PubMed]
74. Cunningham, J.E.; Kelechi, T.; Sterba, K.; Barthelemy, N.; Falkowski, P.; Chin, S.H. Case report of a patient with chemotherapy-
induced peripheral neuropathy treated with manual therapy (massage). Support. Care Cancer 2011, 19, 1473–1476. [CrossRef]
[PubMed]
75. Rostami, N.; Mosavat, S.H.; Heydarirad, G.; Arbab Tafti, R.; Heydari, M. Efficacy of topical Citrullus colocynthis (bitter apple)
extract oil in chemotherapy-induced peripheral neuropathy: A pilot double-blind randomized placebo-controlled clinical trial.
Phytother. Res. 2019, 33, 2685–2691. [CrossRef] [PubMed]
76. Sarısoy, P.; Ovayolu, O. The Effect of Foot Massage on Peripheral Neuropathy-Related Pain and Sleep Quality in Patients with
Non-Hodgkin’s Lymphoma. Holist. Nurs. Pract. 2020, 34, 345–355. [CrossRef] [PubMed]
77. Stephenson, N.; Dalton, J.A.; Carlson, J. The effect of foot reflexology on pain in patients with metastatic cancer. Appl. Nurs. Res.
2003, 16, 284–286. [CrossRef]
78. Wyatt, G.; Sikorskii, A.; Tesnjak, I.; Frambes, D.; Holmstrom, A.; Luo, Z.; Victorson, D.; Tamkus, D. A randomized clinical trial
of caregiver-delivered reflexology for symptom management during breast cancer treatment. J. Pain Symptom Manag. 2017, 54,
670–679. [CrossRef]
79. Doorenbos, A.; Given, B.; Given, C.; Verbitsky, N.; Cimprich, B.; McCorkle, R. Reducing symptom limitations: A cognitive
behavioral intervention randomized trial. Psychooncology 2005, 14, 574–584. [CrossRef]
80. Galantino, M.L.; Tiger, R.; Brooks, J.; Jang, S.; Wilson, K. Impact of somatic yoga and meditation on fall risk, function, and
quality of life for chemotherapy-induced peripheral neuropathy syndrome in cancer survivors. Integr. Cancer Ther. 2019, 18,
1534735419850627. [CrossRef]
81. Giasson, M.; Bouchard, L. Effect of therapeutic touch on the well-being of persons with terminal cancer. J. Holist. Nurs. 1998, 16,
383–398. [CrossRef]
82. Koch, B. Evaluation of Efficacy of Home-Based Kneipp Hydrotherapy in Patients with Polyneuropathic Compaints of the Lower Extremities;
Charité—Universitätsmedizin Berlin: Berlin, Germany, 2015.
83. Listing, M.; Reißhauer, A.; Krohn, M.; Voigt, B.; Tjahono, G.; Becker, J.; Klapp, B.F.; Rauchfuß, M. Massage therapy reduces
physical discomfort and improves mood disturbances in women with breast cancer. Psychooncology 2009, 18, 1290–1299. [CrossRef]
84. McCrary, J.M.; Goldstein, D.; Sandler, C.X.; Barry, B.K.; Marthick, M.; Timmins, H.C.; Li, T.; Horvath, L.; Grimison, P.; Park, S.B.
Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy. Support. Care Cancer 2019,
27, 3849–3857. [CrossRef]
85. Moore, S.; Corner, J.; Haviland, J.; Wells, M.; Salmon, E.; Normand, C.; Brada, M.; Smith, I. Nurse led follow up and conventional
medical follow up in management of patients with lung cancer: Randomised trial. BMJ 2002, 325, 1145. [CrossRef] [PubMed]
86. Ostermann, T.; Blaser, G.; Bertram, M.; Michalsen, A.; Matthiessen, P.F.; Kraft, K. Effects of rhythmic embrocation therapy with
solum oil in chronic pain patients: A prospective observational study. Clin. J. Pain 2008, 24, 237–243. [CrossRef] [PubMed]
87. Post-White, J.; Kinney, M.E.; Savik, K.; Gau, J.B.; Wilcox, C.; Lerner, I. Therapeutic massage and healing touch improve symptoms
in cancer. Integr. Cancer Ther. 2003, 2, 332–344. [CrossRef] [PubMed]
88. Rostock, M.; Jaroslawski, K.; Guethlin, C.; Ludtke, R.; Schröder, S.; Bartsch, H.H. Chemotherapy-Induced Peripheral Neuropathy
in Cancer Patients: A Four-Arm Randomized Trial on the Effectiveness of Electroacupuncture. Evid. Based Complement. Altern.
Med. 2013, 2013, 349653. [CrossRef] [PubMed]
89. Schönsteiner, S.S.; Bauder Mißbach, H.; Benner, A.; Mack, S.; Hamel, T.; Orth, M.; Landwehrmeyer, B.; Süßmuth, S.D.; Geitner, C.;
Mayer-Steinacker, R.; et al. A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy
evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and
physical exercises. Exp. Hematol. Oncol. 2017, 6, 5. [CrossRef]
90. Schwenk, M.; Grewal, G.S.; Holloway, D.; Muchna, A.; Garland, L.; Najafi, B. Interactive Sensor-Based Balance Training in Older
Cancer Patients with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Controlled Trial. Gerontology 2016, 62,
553–563. [CrossRef]
91. Uehleke, B.; Wöhling, H.; Stange, R. A prospective “Study by Correspondance” on the effects of Kneipp hydrotherapy in patients
with complaints due to peripheral neuropathy. Schweiz. Z. Ganzheitsmed. 2008, 20, 287–291. [CrossRef]
92. Nagarathna, R.; Rekha, M.; Vanitha, N.; Kodaganuru, G.; Srinath, B.; Vishweshwara, M.; Madhavi, Y.; Basavalingaiah, S.A.;
Bilimagga, R.S.; Rao, N.; et al. Effects of yoga on symptom management in breast cancer patients: A randomized controlled trial.
Int. J. Yoga 2009, 2, 73–79. [CrossRef]
93. Wong, R.; Major, P.; Sagar, S. Phase 2 Study of Acupuncture-Like Transcutaneous Nerve Stimulation for Chemotherapy-Induced
Peripheral Neuropathy. Integr. Cancer Ther. 2016, 15, 153–164. [CrossRef] [PubMed]
Med. Sci. 2023, 11, 15 33 of 34
94. Zimmer, P.; Trebing, S.; Timmers-Trebing, U.; Schenk, A.; Paust, R.; Bloch, W.; Rudolph, R.; Streckmann, F.; Baumann, F.T.
Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance
and strength in metastasized colorectal cancer patients: A randomized controlled trial. Support. Care Cancer 2018, 26, 615–624.
[CrossRef] [PubMed]
95. Dy, S.M. Evidence-based approaches to pain in advanced cancer. Cancer J. 2010, 16, 500–506. [CrossRef] [PubMed]
96. Tofthagen, C.; Visovsky, C.; Berry, D.L. Strength and Balance Training for Adults with Peripheral Neuropathy and High Risk of
Fall: Current Evidence and Implications for Future Research. Oncol. Nurs. Forum 2012, 39, E416–E424. [CrossRef] [PubMed]
97. Verhulst, A.L.; Savelberg, H.H.; Vreugdenhil, G.; Mischi, M.; Schep, G. Whole-Body Vibration as a Modality for the Rehabilitation
of Peripheral Neuropathies: Implications for Cancer Survivors Suffering from Chemotherapy-Induced Peripheral Neuropathy.
Oncol. Rev. 2015, 9, 263. [CrossRef]
98. Sanft, T.; Denlinger, C.S.; Armenian, S.; Baker, K.S.; Broderick, G.; Demark-Wahnefried, W.; Friedman, D.L.; Goldman, M.;
Hudson, M.; Khakpour, N.; et al. NCCN Guidelines Insights: Survivorship, Version 2.2019: Featured Updates to the NCCN
Guidelines. J. Natl. Compr. Cancer Netw. 2019, 17, 784–794. [CrossRef] [PubMed]
99. Kim, J.-I.; Lee, M.S.; Kang, J.W.; Choi, D.Y.; Ernst, E. Reflexology for the symptomatic treatment of breast cancer: A systematic
review. Integr. Cancer Ther. 2010, 9, 326–330. [CrossRef]
100. Hökkä, M.; Kaakinen, P.; Pölkki, T. A systematic review: Non-pharmacological interventions in treating pain in patients with
advanced cancer. J. Adv. Nurs. 2014, 70, 1954–1969. [CrossRef]
101. Izgu, N.; Ozdemir, L.; Bugdayci, F. Effect of Aromatherapy Massage on Chemotherapy-Induced Peripheral Neuropathic Pain
and Fatigue in Patients Receiving Oxaliplatin: An Open Label Quasi-Randomized Controlled Pilot Study. Cancer Nurs. 2019, 42,
139–147. [CrossRef]
102. Armstrong, T.; Almadrones, L.; Gilbert, M.R. Chemotherapy-induced peripheral neuropathy. Oncol. Nurs. Forum 2005, 32,
305–311. [CrossRef] [PubMed]
103. Jane, S.W.; Wilkie, D.J.; Gallucci, B.B.; Beaton, R.D. Systematic review of massage intervention for adult patients with cancer: A
methodological perspective. Cancer Nurs. 2008, 31, E24–E35. [CrossRef]
104. Aghabati, N.; Mohammadi, E.; Pour Esmaiel, Z. The effect of therapeutic touch on pain and fatigue of cancer patients undergoing
chemotherapy. Evid. Based Complement. Altern. Med. 2010, 7, 375–381. [CrossRef] [PubMed]
105. Grealish, L.; Lomasney, A.; Whiteman, B.J.C.N. Foot massage: A nursing intervention to modify the distressing symptoms of pain
and nausea in patients hospitalized with cancer. Cancer Nurs. 2000, 23, 237–243. [CrossRef]
106. Long, H.A.; French, D.P.; Brooks, J.M. Optimising the value of the critical appraisal skills programme (CASP) tool for quality
appraisal in qualitative evidence synthesis. Res. Methods Med. Health Sci. 2020, 1, 31–42. [CrossRef]
107. Holey, E.A.; Cook, E.M. Evidence-Based Therapeutic Massage E-Book: A Practical Guide for Therapists; Elsevier Health Sciences:
Amsterdam, The Netherlands, 2012.
108. Layer, M. (Ed.) Praxishandbuch Rhythmische Einreibungen nach Wegman/Hauschka; Verlag Hans Huber: Bern, Switzerland, 2014.
109. Frank, L.S.; Frank, J.L.; March, D.; Makari-Judson, G.; Barham, R.B.; Mertens, W.C. Does therapeutic touch ease the discomfort or
distress of patients undergoing stereotactic core breast biopsy? A randomized clinical trial. Pain Med. 2007, 8, 419–424. [CrossRef]
110. Samarel, N.; Fawcett, J.; Davis, M.M.; Ryan, F.M. Effects of dialogue and therapeutic touch on preoperative and postoperative
experiences of breast cancer surgery: An exploratory study. Oncol. Nurs. Forum 1998, 25, 1369–1376. [PubMed]
111. Tabatabaee, A.; Tafreshi, M.; Rassouli, M.; Aledavood, S.; Majd, H.; Farahmand, A. Effect of therapeutic touch in patients with
cancer: A literature review. Med. Arch. 2016, 70, 142. [CrossRef] [PubMed]
112. Büntzel, J.; Micke, O.; Büntzel, J. How to transfer traditional knowledge about medicinal herbs? or TCM plants: A black box for
modern oncologists. J Cancer Res. Clin. Oncol. 2021, 147, 351–359. [CrossRef]
113. Steflitsch, W.; Wolz, D.; Buchbauer, G.; Stadelmann, I. (Eds.) Aromatherapie in Wissenschaft und Praxis; Stadelmann Natur:
Wiggensbach, Germany, 2021.
114. Maßberg, D.; Hatt, H. Human Olfactory Receptors: Novel Cellular Functions Outside of the Nose. Physiol. Rev. 2018, 98,
1739–1763. [CrossRef]
115. Kontaris, I.; East, B.S.; Wilson, D.A. Behavioral and Neurobiological Convergence of Odor, Mood and Emotion: A Review. Front.
Behav. Neurosci. 2020, 14, 35. [CrossRef]
116. National Center for Complementary and Integrative Health. 2017. Available online: https://www.nccih.nih.gov/health/mind-
and-body-practices (accessed on 19 April 2022).
117. Danon, N.; Al-Gobari, M.; Burnand, B.; Rodondi, P. Are mind-body therapies effective for relieving cancer-related pain in adults?
A systematic review and meta-analysis. Psychooncology 2022, 31, 345–371. [CrossRef] [PubMed]
118. Carlson, L.E.; Zelinski, E.; Toivonen, K.; Flynn, M.; Qureshi, M.; Piedalue, K.-A.; Grant, R. Mind-body therapies in cancer: What is
the latest evidence? Curr. Oncol. Rep. 2017, 19, 67. [CrossRef] [PubMed]
119. Siemens, W.; Boehlke, C.; Bennett, M.I.; Offner, K.; Becker, G.; Gaertner, J. Transcutaneous electrical nerve stimulation for
advanced cancer pain inpatients in specialist palliative care-a blinded, randomized, sham-controlled pilot cross-over trial. Support
Care Cancer 2020, 28, 5323–5333. [CrossRef] [PubMed]
120. Lesenskyj, A.M.C.; Cruciani, R. Optimizing Neuropathic Pain Relief with Scrambler Therapy. Pract. Pain Manag. 2017, 17, 1.
Med. Sci. 2023, 11, 15 34 of 34
121. Tomasello, C.; Pinto, R.M.; Mennini, C.; Conicella, E.; Stoppa, F.; Raucci, U. Scrambler therapy efficacy and safety for neuropathic
pain correlated with chemotherapy-induced peripheral neuropathy in adolescents: A preliminary study. Pediatr. Blood Cancer
2018, 65, e27064. [CrossRef]
122. Karri, J.; Marathe, A.; Smith, T.J.; Wang, E.J. The Use of Scrambler Therapy in Treating Chronic Pain Syndromes: A Systematic
Review. Neuromodulation 2022, 6, S1094–7159(22)00681-X. [CrossRef]
123. Höxtermann, M.D.; Haller, H.; Aboudamaah, S.; Bachemir, A.; Dobos, G.; Cramer, H.; Voiss, P. Safety of acupuncture in oncology:
A systematic review and meta-analysis of randomized controlled trials. Cancer 2022, 128, 2159–2173. [CrossRef]
124. Cramer, H.; Lauche, R.; Klose, P.; Lange, S.; Langhorst, J.; Dobos, G.J. Yoga for improving health-related quality of life, mental
health and cancer-related symptoms in women diagnosed with breast cancer. Cochrane Database Syst. Rev. 2017, 1, Cd010802.
[CrossRef]
125. Loprinzi, C.L.; Lacchetti, C.; Bleeker, J.; Cavaletti, G.; Chauhan, C.; Hertz, D.L.; Kelley, M.R.; Lavino, A.; Lustberg, M.B.; Paice,
J.A.; et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO
Guideline Update. J. Clin. Oncol. 2020, 38, 3325–3348. [CrossRef]
126. Klafke, N.; Homberg, A.; Glassen, K.; Mahler, C. Addressing holistic healthcare needs of oncology patients: Implementation
and evaluation of a complementary and alternative medicine (CAM) course within an elective module designed for healthcare
professionals. BMC Complement. Ther. Med. 2016, 29, 190–195. [CrossRef]
127. Homberg, A.; Klafke, N.; Loukanova, S.; Glassen, K. Findings from a three-round Delphi study: Essential topics for inter-
professional training on complementary and integrative medicine. BMC Complement. Med. Ther. 2020, 20, 348. [CrossRef]
[PubMed]
128. Gupta, M.; Mamgain, R.K.; Mamgain, P.; Verma, S.K.; Pruthi, D.S.; Kandwal, A.; Saini, S. The efficacy of an ayurvedic preparation
of yashtimadhu (Glycyrrhiza glabra) on radiation-induced mucositis in head-and-neck cancer patients: A pilot study. J. Cancer Res.
Ther. 2020, 16, 458–462. [CrossRef]
129. Rastogi, S.; Tiwari, V.; Jatav, S.P.; Singh, N.; Verma, S.; Verma, S.; Sharma, K.G.; Pandey, P.; Singh, G. A survey of patients visiting
an Ayurvedic teaching hospital for factors influencing the decision to choose ayurveda as a health care provider. J. Ayurveda
Integr. Med. 2022, 100539. [CrossRef] [PubMed]
130. Wortmann, J.K.; Bremer, A.; Eich, H.; Wortmann, H.K.; Schuster, A.; Fühner, J.; Büntzel, J.; Muecke, R.; Prott, F.; Huebner, J. Use of
complementary and alternative medicine by patients with cancer: A cross-sectional study at different points of cancer care. Med.
Oncol. 2016, 33, 78. [CrossRef] [PubMed]
131. Shorofi, S.A.; Arbon, P. Complementary and alternative medicine (CAM) among Australian hospital-based nurses: Knowledge,
attitude, personal and professional use, reasons for use, CAM referrals, and socio-demographic predictors of CAM users.
Complement. Ther. Clin. Pract. 2017, 27, 37–45. [CrossRef] [PubMed]
132. Cırık, V.; Efe, E. Pediatric Nurses’ Usage and Experience Toward Complementary Health Approaches. J. Altern. Complement. Med.
2018, 24, 1120–1127. [CrossRef]
133. Bhoo-Pathy, N.; Subramaniam, S.; Khalil, S.; Kimman, M.; Kong, Y.-C.; Ng, C.-W.; Bustamam, R.S.; Yip, C.-H. Out-of-Pocket Costs
of Complementary Medicine Following Cancer and the Financial Impact in a Setting with Universal Health Coverage: Findings
from a Prospective Cohort Study. JCO Oncol. Pract. 2021, 17, e1592–e1602. [CrossRef] [PubMed]
134. Chang, H.Y.; Chang, H.L. A review of nurses’ knowledge, attitudes, and ability to communicate the risks and benefits of
complementary and alternative medicine. J. Clin. Nurs. 2015, 24, 1466–1478. [CrossRef]
135. Bossert, J.; Mahler, C.; Boltenhagen, U.; Kaltenbach, A.; Froehlich, D.; Szecsenyi, J.; Wensing, M.; Joos, S.; Klafke, N. Protocol
for the process evaluation of a counselling intervention designed to educate cancer patients on complementary and integrative
health care and promote interprofessional collaboration in this area (the CCC-Integrativ study). PLoS ONE 2022, 17, e0268091.
[CrossRef]
136. Peters, M.D.J.; Godfrey, C.M.; Khalil, H.; McInerney, P.; Parker, D.; Soares, C.B. Guidance for conducting systematic scoping
reviews. Int. J. Evid. Based Healthc. 2015, 13, 141–146. [CrossRef] [PubMed]
137. van der Steen, J.T.; ter Riet, G.; van den Bogert, C.A.; Bouter, L.M. Causes of reporting bias: A theoretical framework. F1000Research
2019, 8, 280. [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual
author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to
people or property resulting from any ideas, methods, instructions or products referred to in the content.